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of these clinically relevant bacteria have 
developed resistance to most currently 
available antibiotics.[1] It is estimated that 
during the last decade, direct cost caused 
by antimicrobial-resistant bacteria is 
€1.5 billion per year in the EU, Iceland, 
and Norway.[4] Consequently, novel agents 
that control the growth of these human 
pathogens are urgently required.[5] Evalu-
ation of the synergistic effects of existing 
drugs and investigation of the inhibitory 
activity of numerous naturally occurring 
compounds against pathogenic bacteria 
are also regarded as important approaches 
in the search for novel treatment options.
The currently available high-throughput 
screening methods based on multi-well 
microplates are time-consuming and 
costly, requiring expensive robotics for 
plate handling and pipetting.[6] Further-
more, this type of screening requires 
relatively large amounts of expensive reagents, and microtiter 
plates. Most antibiotic resistance analyses are based on defined 
protocols for routine testing, and the cost of the modifications 
required to screen newly identified natural compounds and 
synergistic effects with other compounds are prohibitive for 
many research and development (R&D) laboratories.
Alternative methods have been developed for specific appli-
cations. Choi et al. developed a paper-based array to screen the 
electricity-producing bacteria.[7] In another study, a growth chip 
with a porous aluminum oxide layer containing small cavities 
was used to culture and screen microorganisms. With a cavity 
size of 7 × 7  µm and up to one million cavities per chip, this 
method offers the capacity for very high-throughput screening 
Currently, there are no time-saving and cost-effective high-throughput 
screening methods for the evaluation of bacterial drug-resistance. In this 
study, a droplet microarray (DMA) system is established as a miniaturized 
platform for high-throughput screening of antibacterial compounds using 
the emerging, opportunistic human pathogen Pseudomonas aeruginosa 
(P. aeruginosa) as a target. Based on the differences in wettability of DMA 
slides, a rapid method for generating microarrays of nanoliter-sized droplets 
containing bacteria is developed. The bacterial growth in droplets is evalu-
ated using fluorescence. The new method enables immediate screening with 
libraries of antibiotics. A novel simple colorimetric readout method compat-
ible with the nanoliter size of the droplets is established. Furthermore, the 
drug-resistance of P. aeruginosa 49, a multi-resistant strain from an environ-
mental isolate, is investigated. This study demonstrates the potential of the 
DMA platform for the rapid formation of microarrays of bacteria for high-
throughput drug screening.
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1. Introduction
The increasing incidence of antimicrobial resistance in bac-
teria and the lack of new antibiotics that can be used to treat 
drug-resistant bacterial infections have become a major threat 
to human health worldwide.[1–3] The development of anti-
biotic resistance among various bacteria belonging to the 
“ESKAPE” group of human facultative pathogenic bacteria 
is a particular cause for concern. The ESKAPE group of bac-
teria comprises Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa (P. aeruginosa), and Enterobacter spp., which are 
known causes of serious hospital-acquired infections.[2] Several 
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although single cavities cannot be used to assess the effective-
ness of antimicrobial substance.[8] Despite the advantages of 
these alternative techniques, the difficulties associated with pro-
duction and high cost remain.
Recently, we introduced the droplet-microarray platform 
(DMA) with precisely separated superhydrophobic and hydro-
philic areas.[9] By wetting the DMA with aqueous solutions, we 
can create an array of small (90 nL), spatially separated drop-
lets. These micro-reservoirs contain sufficient liquid to provide 
an appropriate environment for the growth of eukaryotic cells 
and prevent cross-contamination, with the additional advan-
tages of ease of handling and few pipetting steps. The DMA 
platform also facilitates the simultaneous analysis of a library of 
substances in parallel by sandwiching compounds printed glass 
slides with DMA slides.[10] Thus, the DMA platform represents 
a simple, rapid, and highly cost-effective method of screening 
the antibacterial effects of a variety of substances.
Here, we present the DMA platform as a novel and cost-
effective technology for performing miniaturized high-
throughput screening of bacteria to accelerate the detection 
of antibiotic-resistant microbes in samples from patients and 
environments. In this study, we used P. aeruginosa as a target 
strain since this opportunistic Gram-negative human faculta-
tive pathogenic bacterium is known to cause a plethora of hos-
pital infections, including respiratory, urinary tract, and wound 
infections.[11,12] Moreover, this pathogen is well-known for its 
high intrinsic resistance against a variety of different antibi-
otics and disinfectants.[13] Therefore, due to the extensive use of 
antibiotics in hospitals, acquired multidrug-resistance among 
P. aeruginosa is a major concern.[14] Thus, in this study, we vali-
dated the DMA screening platform using clinically applied anti-
biotics to investigate the antibiotic-resistance of the multi-drug 
resistant P. aeruginosa 49 isolate.
2. Results and Discussion
2.1. Growth of P. aeruginosa PAO1 GFP on DMA
A schematic representation of bacterial seeding and prolif-
eration on DMA slides is shown in Figure  1a. Aqueous solu-
tions applied onto this slide spontaneously form an array of 
separated microdroplets due to the difference in wettability 
of the hydrophilic square and the superhydrophobic borders 
(Figure 1b; Table S1, Supporting Information). 1.5 mL droplet 
of bacterial suspension was placed onto the superhydrophobic-
hydrophilic array for 30 s before the slide was tilted to form 
microdroplets containing bacteria. Each DMA slide (7.5 × 
2.5 cm) contains three microarray pattern compartments con-
taining 196 hydrophilic squares (Figure  1c). With one DMA 
slide, 588 droplets in few seconds were formed, where each 
droplet representing an individual compartment for subse-
quent antimicrobial testing.
The distributed volume of droplets on DMA slides was evalu-
ated with a pattern size of 1 mm. Figure 1d shows a Gaussian 
distribution of the droplet volume, with the volumes of more 
than 80% of the droplets ranging from 70 nL to 130 nL. Based 
on this information, single droplets of 90 nL were used in the 
subsequent experiments. The distribution of the radius and 
height of the droplets are shown in Figure S1, Supporting 
Information.
First, P. aeruginosa PAO1 expressing GFP (P. aeruginosa 
PAO1 GFP) was used to evaluate the growth of bacteria after 
seeding on DMA slides since the expression of this protein 
facilitates direct microscopic monitoring of bacterial persis-
tence or growth. The distribution of initial bacteria number in 
each droplet after seeding is shown in Figure S2a, Supporting 
Information. There were 109  ± 54 bacteria in each droplet on 
average. DMA slides were placed in a humidity box, which 
was a sealed plastic box with a piece of wet tissue in it. Figure 
S2b, Supporting Information, shows that the high humidity 
in the box could prevent the evaporation of droplets on DMA 
slides. The mass of droplets on DMA slides placed in air was 
decreased from 0.066  ± 0.001  g to 0.001±0.001  g  in 25  min at 
room temperature. While the mass of droplets on DMA slides 
placed in the humidity box was decreased from 0.069 ± 0.003 g 
to 0.060±0.003 g in 15 min and didn't change much in the next 
2 h. The mass change of droplets incubated in the humidity box 
over 24 h at 37  °C was measured as well. It shows that more 
than 77% of the volume of droplets remained on the DMA after 
incubation. To investigate the effect of pattern size on bacterial 
growth, three hydrophilic square pattern sizes were applied to 
DMA slides. Bacteria on DMA slides with hydrophilic spots of 
1  mm and 3  mm shows both bright green fluorescence after 
incubation for 24 h, which was visually comparable with the 
fluorescence of bacteria grown in 96-well plates (Figure  1e). 
Digital images of the bacterial spots were quantified for the 
fluorescence intensity using the software ImageJ. Here, the 
fluorescence intensity of all spots was normalized to the fluo-
rescence intensity of bacteria grown in 96-well plates after 24 h 
incubation to investigate whether growth of bacteria would be 
affected in small volume. The fluorescence intensity of bacteria 
on DMA slides with hydrophilic spots of 0.5  mm was 0.35  ± 
0.06 fluorescence units, which was much lower than the fluo-
rescence intensity of the bacteria in 96-well plates. This result 
suggested that the small volumes of the 0.5  mm hydrophilic 
spots contained not enough cells of P. aeruginosa PAO1 for 
fluorescence signal evaluation. Therefore, the 1  mm spot pat-
tern was used to form droplets on one DMA slide for further 
applications, rather than 3  mm pattern for DMA production. 
The density of bacteria on the DMA slide was 1.8 × 109 ± 0.9 × 
109 CFU mL−1, which was close to the density of bacteria (2.0 × 
109 ± 0.6 × 109 CFU mL−1) incubated in 96-well plates (Figure 1g; 
Table S2, Supporting Information). Both fluorescence imaging 
and bacterial density results confirmed that the DMA slides 
with hydrophilic spots of 1  mm support the persistence and 
growth of bacteria in individual microdroplets.
2.2. DMA as a Screening Platform
Aiming at a single step screening approach, the sandwiching 
process was evaluated using nano-liter amounts of antibiotics 
being transferred into individual bacterial droplets. Antibiotics 
were preprinted onto a fluorinated glass slide with the I-DOT 
instrument and then accurately placed into contact with the bac-
terial droplets on DMA slides using the CellScreenChip (CSC) 
(Figure 2a,b; Figure S3, Supporting Information). Figure 2c–h 
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shows the results of the test using vancomycin at 13.5 µm (inef-
fective for inhibition of P. aeruginosa PAO1 growth) and cipro-
floxacin at 40 µm (effective for inhibition of P. aeruginosa PAO1 
growth) printed in on the DMA in a predesigned pattern.[15] 
Figure 2c confirms the absence of cross-contamination during 
the sandwiching process between the droplets containing cip-
rofloxacin (no strong green fluorescence) and the neighboring 
droplets containing vancomycin (bright green fluorescence). A 
scan of the fluorescence intensity of each droplet is shown in 
Figure 2d. Furthermore, we used this sandwiching method to 
stain the droplets with 5-cyano-2,3-ditolyl-tetrazolium chloride 
(CTC), which is converted to the red fluorescent molecule CTC-
formazan by metabolically active cells. A shown in Figure 2e,f, 
the bacteria showed bright red fluorescence in droplets 
containing vancomycin, which was not observed in droplets 
containing ciprofloxacin being directed against the sensitive 
strain of P. aeruginosa. The growth of bacteria can also be visu-
ally evaluated, with droplets containing actively dividing bac-
teria appearing opaque after drying, while the droplets without 
high-density bacteria appear transparent (Figure 2g). We specu-
late that the difference in transparency is caused by the deposi-
tion of living bacteria and as well as the formation of a biofilm 
on the DMA surface since the printed vancomycin was not able 
to prevent the multiply of bacteria. Then the layer of bacteria 
reflects light leading to a brighter, opaquer surface (Figure 2g). 
This hypothesis was supported by the SEM images shown in 
Figure 2i,j. A layer of bacteria was observed on the white spots, 
while there was no such bacterial film on the transparent spots. 
Figure 1. Growth of P. aeruginosa PAO1 GFP on DMA slides. a) Scheme of bacteria seeding on DMA. b) Photographs of droplets of water on the hydro-
phobic border (left) and hydrophilic square (right) of the DMA surface with the corresponding static water contact angle. c) Digital image of DMA after 
droplets of Basal Medium 2 (BM2) medium formed. d) Distribution of droplet volume on DMA slides. e) Fluorescence images of P. aeruginosa PAO1 
GFP incubated for 24 h on the DMA slide and in a 96-well plate. 500 µm, 1 mm, and 3 mm are the edge length of the hydrophilic square. f) Growth of 
P. aeruginosa PAO1 GFP strain in 96-well plates and on DMA surfaces detected by measuring mean fluorescent intensity per pixel of cultured bacteria. 
All fluorescence intensity values were normalized against P. aeruginosa PAO1 GFP cultured for 24 h in 96-well plates. Data were presented as mean ± 
SD of three experiments with three repeats each time. P-values <0.05 were considered statistically significant. g) Bacterial density in 96-well plate and 
on DMA surfaces after incubation for 24 h. Data were presented as mean ± SD of three experiments with three repeats each time.
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Figure 2. Droplet microarray as a screening platform. a) Scheme of the sandwiching process for screening antibiotics. b) Predesigned pattern of 
printed antibiotics on fluorinated glass slides. c) Image of green fluorescence of the bacteria on DMA with 25 (5 × 5) spots treated sequentially with 
vancomycin (13.5 µm) or ciprofloxacin (40 µm). d) Scan of fluorescence intensity across the yellow line shown in (c). e) Image of red fluorescence of 
active bacteria on DMA with 25 (5 × 5) spots treated sequentially with vancomycin (13.5 µm) or ciprofloxacin (40 µm), and stained with CTC using 
the sandwiching method. f) Scan of fluorescence intensity across the yellow line shown in (e). g) Digital image of DMA surface of the bacteria on 
DMA with 25 (5 × 5) spots treated sequentially with vancomycin (13.5 µm) or ciprofloxacin (40 µm)). The DMA slide was placed on black color paper. 
h) Grayscale scan of the yellow line shown in (g). i) SEM image of the transparent hydrophilic spot on DMA surface in (g). j) SEM image of opaque 
hydrophilic spots of DMA surface in (g).
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This visually detectable readout of bacterial growth on DMA 
surfaces has the advantage over the other approaches that no 
expensive device is required.
As an antibiotic screening platform, the DMA should give 
comparable results to those obtained using a microtiter plate-
based method. Hence, the MIC (Minimal Inhibition Concen-
tration) of five antibiotics were investigated with P. aeruginosa 
PAO1 GFP assayed on DMA surfaces and in 96-well plates. The 
MIC is the lowest concentration of antimicrobial compounds 
that is able to inhibit the growth of bacteria in an overnight 
assay based on the determination of the OD600 value. As shown 
in Figure 3, the MIC values of ceftazidime on DMA slides and 
in 96-well plates were both in the range of 6–60 µm. The MIC 
values of ciprofloxacin on DMA slides and in 96-well plates 
were both in the 0–1 µm range. The MIC value of tobramycin 
on DMA slides was in the 2–20 µm range, while the MIC was 
in the 0–2 µm range in 96-well plate, although values were 
consistent with the range of MIC values listed in EUCAST 
database (0–68 µm). Ampicillin and tetracycline were shown 
to be ineffective antibiotics for P. aeruginosa PAO1 in both the 
DMA slide and 96-well plate assays. The time dependence of 
the antimicrobial effect of polymyxin B was also investigated on 
DMA slides and in the 96-well plate. As shown in Figure  3f, 
the number of living bacteria was reduced by exposure to poly-
myxin B in a time-dependent manner inactivating all bacteria 
on the DMA slides and in the 96-well plates in the first 2 h 
incubation. These observations confirm that the small volume 
of the droplet on a DMA slide does not influence the kinetics of 
the antibacterial effect of polymyxin B on P. aeruginosa PAO1.
2.3. Antibiotic Resistance Study of P. aeruginosa 49 on 
DMA Slides
As a new methodology, the DMA platform shows promising 
potential in facilitating and advancing antibiotic resistance 
studies of bacteria derived from patients or the environment. 
We investigated the ability of 18 antibiotics at two concentra-
tions to inhibit growth of P. aeruginosa 49 on DMA slides and 
in a 96-well plate as a proof of principle to identify antibiotic 
resistance. P. aeruginosa 49 were isolated from clinical waste-
water from the sewer close to the surgery department and from 
the clinical wastewater collection pipes Germany.[16] Berditsch 
et al. reported that P. aeruginosa 49 are resistant to gentamicin, 
ciprofloxacin, imipenem, ceftazidime, amikacin, azlocillin, 
and piperacillin-tazobactam with using disk diffusion assay.[17] 
Here, a number of 18 antibiotics have been chosen of various 
categories of antibiotic; include β-lactam antibiotic (cepha-
losporins, ceftazidime, imipenem, meropenem, amoxicillin, 
carbenicillin, ampicillin, methicillin), quinolone antibiotic 
Figure 3. a–e) MIC of ciprofloxacin, ceftazidime, tobramycin, ampicillin and tetracycline for P. aeruginosa PAO1 GFP assayed in 96-well plates and on 
DMA surfaces (DMA slides: readout by fluorescence intensity and the intensities were converted into OD values (Figure S4, Supporting Information); 
96-well plates: readout by OD measurement). All results were normalized to a blank control (0 µm in 96-well plates). Data were presented as mean 
± SD of three experiments with 10 repeats each time. f) Time-course assay of the antibacterial activity of polymyxin B on P. aeruginosa PAO1 on DMA 
slides. Data were presented as mean ± SD of three experiments with 5 repeats each time.
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(ciprofloxacin), antimicrobial peptides (polymyxin B), macrolide 
antibiotic (erythromycin), tetracycline antibiotics (tetracycline), 
aminoglycoside antibiotic (kanamycin sulfate, streptomycin, 
tobramycin), sulfonamides (sulfamethoxazole), chloramphen-
icol antibiotic (chloramphenicol), and combinations (pipera-
cillin–tazobactam). We used the MIC concentration obtained 
from EUCAST database of P. aeruginosa as reference (Table 
S3, Supporting Information). We also tested 10-fold MIC con-
centrations to reveal the sensitivity of P. aeruginosa 49 to these 
antibiotics. The antibiotics were transferred into P. aeruginosa 
49 droplets using the sandwiching method. After incubation for 
24 h, the DMA slides were dried in air. Opaque spots (bacte-
rial growth has not been inhibited) indicated the lack of anti-
biotic effectiveness, while transparent (bacterial growth has 
been inhibited) spots revealed that the antibiotic was effec-
tive. In 96-well plates, wells with high turbidity suggested the 
lack of antibiotic effectiveness, while low turbidity/transparent 
suggested that the antibiotic was effective. All the result was 
readout visually. Figure 4a shows that, with the exception of cef-
tazidime and polymyxin B, P. aeruginosa 49 was not sensitive 
to the chosen MIC concentrations of antibiotics. However, 
piperacillin-tazobactam, cefotaxime, amoxicillin, carbenicillin, 
and ampicillin inhibited the growth of P. aeruginosa 49 at the 
high concentration (10 × MIC). According to the universal defi-
nition of drug-resistance, Pseudomonas bacteria are defined as 
multidrug-resistant bacteria if the strain is resistant to some of 
antimicrobial agents from the following four categories: peni-
cillins + β-lactamase inhibitors, cephalosporins, carbapenems, 
and fluoroquinolones.[18] As shown in Figure 4b, P. aeruginosa 
49 isolated from waste-water was identified as a multidrug-
resistant bacterial strain. The sensitivity of P. aeruginosa 49 
to polymyxin B and ceftazidime tested on DMA slides and in 
96-well plates is shown in Figure S5, Supporting Information. 
The MIC value of the two antibiotics read from DMA slides and 
96-well plates were the same, that is, 2 mg mL−1 for ceftazidime 
and 4 mg mL−1 for polymyxin B.
Figure 4. Screening result of antibiotic effectiveness against P. aeruginosa 49 on DMA surfaces and in 96-well plates. Two concentrations of antibiotics 
were tested. The MIC value of antibiotics was obtained from the EUCAST database. In 96-well plates, antibiotics were transferred into the bacterial 
suspension (100 µL per well) with pipetting. On DMA surfaces, antibiotics were transferred into droplets of bacterial solution using the sandwiching 
method. Initial bacterial density: OD600 = 0.001. The bacteria were incubated with antibiotics for 24 h at 37 °C. The antibiotic activity was evaluated by 
visual inspection of the transparency of the wells or droplets (opacity indicates live bacteria). Three experiments with 10 repeats (10 wells and 10 spots) 
of each concentration of antibiotics were performed. The antibiotic was defined as effective when there were ≥ 8 wells or spots were transparent. S is 
sensitive; NS is not sensitive.
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3. Conclusion
A novel platform for culturing bacteria in spatially separated 
micro-reservoirs filled with a medium was established. This 
DMA platform can be used for screening the efficiency of clin-
ically used antibiotics against bacterial pathogens. The advan-
tages of the DMA platform are ease of handling, almost no 
pipetting steps in creating hundreds of micro-reservoirs, and 
parallel testing of chemical compounds in minute amounts 
for screening full drug libraries. This platform offers the 
ability to investigate drug-resistance of bacteria isolated from 
patients and the environment with minimal cost and effort. 
As a proof of principle, P. aeruginosa PAO1 as well as the 
multi-drug resistant P. aeruginosa PA49 isolate could be grown 
successfully on the DMA surfaces within 24 h. Here, the dif-
ferent categories of antibiotics were applied by sandwiching a 
fluorinated glass slide preprinted with the drugs to the DMA 
containing bacteria. The growth of the bacterial culture on 
DMA slides can be visualized by microscopy using a GFP 
expressing strain PAO1::GFP or applying a staining method. 
Furthermore, bacterial growth can be detected and evaluated 
by visual examination of the turbidity/transparency of the 
hydrophilic spots. In parallel and as a control, the obtained 
DMA screening results were comparable to those using a con-
ventional 96-well plate assay against a multi-drug resistant 
P. aeruginosa strain.
In further studies, the DMA platform will be used to identify 
potential natural or synthetic drug candidates for the treatment 
of bacterial infections. In extension, this DMA platform opens 
the opportunity to study the synergetic effects of combinatorial 
drug treatment.
4. Experimental Section
Materials and Instruments: Patterned superhydrophobic-hydrophilic 
glass slides (7.5 × 2.5  cm) were obtained from Aquarray GmbH 
(Eggenstein–Leopoldshafen, Germany). Each slide had three 
compartments, each containing 196 (14 × 14) square-shaped hydrophilic 
spots (1 × 1  mm). The distance between hydrophilic spots was 
500  µm. Ethanol, potassium phosphate, (NH4)2SO4, MgSO4, FeSO4, 
NaOH, HCl, and glucose were from Merck (Darmstadt, Germany). 
Müller–Hinton (MH) medium was purchased from Merck (Darmstadt, 
Germany). Glass slides (Nexterion Glass B) were purchased from 
Schott (Jena, Germany). (1H, 1H, 2H, 2H-perfluorooctyl) silane 
was purchased from Sigma-Aldrich (Munich, Germany). CTC was 
purchased from Polysciences Europe GmbH (Hirschberg an der 
Bergstrasse, Germany). Ciprofloxacin was purchased from Fluka 
(Seelze, Germany). Ceftazidime and tazobactam were purchased 
from ACROS ORGANICS (Geel, Belgium). Tobramycin, cefotaxime, 
amoxicillin, ampicillin, polymyxin B, methicillin, erythromycin, 
kanamycin sulfate, sulfamethoxazole, and tetracycline were purchased 
from Sigma-Aldrich (Munich, Germany). Piperacillin was purchased 
from Alfa Aesar (Kandel, Germany). Imipenem and meropenem 
were purchased from Cayman Chemical Company (Michigan, USA). 
Chlorampenicol was purchased from AppliChem (Darmstadt, 
Germany). Streptomycin was purchased from Carl Roth (Karlsruhe, 
Germany).
The AxioImage M2 system equipped with an Apotome (Carl Zeiss, 
Oberkochen, Germany) was used for fluorescence microscopy. A DSA 
25 contact angle goniometer (Krüss, Germany) was used for water 
contact angle measurement. The I-DOT non-contact liquid dispenser 
was purchased from Dispendix (Stuttgart, Germany).
Bacterial Strain, Medium Preparation, and Culture Conditions: 
Pseudomonas aeruginosa strain PAO1 was used as a screening target 
in this study.[19] This strain was tagged by introducing plasmid 
pUCP20::GFP by electroporation, resulting in the production of the green 
fluorescent protein (GFP) to facilitate monitoring of P. aeruginosa PAO1 
(designated P. aeruginosa PAO1 GFP) by fluorescence microscopy.[20] 
P. aeruginosa PAO1 GFP was routinely grown in Müller–Hinton (MH) 
broth medium overnight at 37°C. The bacterial suspension was adjusted 
to OD600 = 0.1 with minimal medium Basal Medium 2 (BM2) and then 
diluted 1:100 with BM2 medium to obtain a bacterial suspension of 106 
colony forming units CFU mL−1. Pseudomonas aeruginosa strain PA49 
(designated P. aeruginosa PA49) was cultured in BM2 medium overnight 
at 37°C.[16] The bacterial suspension was adjusted to OD600  = 0.1 with 
BM2 and then diluted 1:100 with BM2 medium to obtain a bacterial 
suspension of 106 CFU mL−1.
Seeding and Culture of Bacteria on the DMA Slide: 1.5 mL of solution 
was added to one of the three compartments of squares on the DMA 
slide ensuring that all 196 spots were covered. The droplet was left to 
stand for 30 s to allow the bacteria to settle. The slide was then quickly 
tilted and the droplets formed spontaneously as the liquid flowed 
away. A non-contact liquid dispenser can be used to significantly 
reduce the amount of bacterial sample, provided the dead-volume of a 
corresponding dispenser is low.
For incubating bacterial cells, the DMA slide was placed inside a 
Petri dish within a box with wetted tissues that was closed to prevent 
evaporation. The box was placed in an incubator at 37°C and the bacteria 
were cultured for the required period of time.
To calculate the volume of droplets on the DMA, droplets on DMA 
slides were prepared first. The height (H), and radius (r) of droplets were 
measured with a DSA 25 contact angle goniometer (Krüss, Hamburg, 
Germany). The volume of the droplets was then calculated based on the 
assumption that the droplets formed part of a spherical cap.
To enumerate the bacteria on DMA slides, one of the three 
compartments in the DMA slide, which contained 196 bacterial droplets 
on its surface, was immersed into 20  mL BM2 medium and vortexed 
for 60 s. The suspension was then serially diluted with cell wash buffer 
and 10 µL of the dilutions were seeded on Luria broth (LB) agar plates. 
After incubation for 24 h at 37°C, the colony number on LB agar plates 
was recorded used to estimate the number of bacteria on the DMA slide. 
Details of the estimation are shown in the supporting information.
Printing of Antibiotics onto Fluorinated Glass Slides: Glass slides were 
cleaned by immersion in 1 m NaOH solution for 1 h, washed with water 
for 30 s, and then immersed in 1 m HCl for 30 min. After washing with 
water for 30 s, the cleaned glass slides were fluorinated by incubation 
overnight with 30  µL trichloro (1H, 1H, 2H, 2H-perfluorooctyl) silane 
in a pressurized (50 mbar) desiccator. Antibiotics were printed onto 
the slides using the I-Dot non-contact liquid dispenser. The antibiotics 
ceftazidime, tobramycin, ampicillin, vancomycin, tetracycline, 
piperacillin, erythromycin, amoxicillin, and carbenicillin were dissolved 
in DMSO (2  mg mL−1) whereas ciprofloxacin, polymyxin B, imipenem, 
and meropenem were dissolved in sterile water (2  mg mL−1). Further 
dilutions were performed with sterile water to obtain the appropriate 
amount of antibiotics per square with a printable volume ranging 
between 5 nL and 100 nL. After printing with antibiotics, the DMA slides 
were dried in air to remove traces of DMSO.
Sandwiching DMA with Preprinted Antibiotics: To expose the 
bacteria to antibiotics, an antibiotic preprinted slide was sandwiched 
with the DMA slide using the CellScreenChip (CSC, as described in 
Figure S3, Supporting Information). This novel instrument allows 
the precise alignment of two glass slides while controlling the 
distance between them. The DMA slide and the antibiotic printed 
slide were clamped into the lower and upper frames of the CSC, 
respectively. The distance between the two frames was controlled by 
four micro-screws, fixed at a specific height. The CSC was closed and 
aligned by four pillars located at the corners of the lower frame that 
are positioned to align with four reference holes in the upper frame. 
In this way, the bacteria-containing droplets on the DMA slide were 
placed in contact with the antibiotic imprinted slide without excess 
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pressure. Since the antibiotics were printed in a specific pattern 
correlating to the DMA slide, the mirror image of the printed pattern 
was observed on the DMA slide after sandwiching. Sandwiching was 
carried immediately after the bacteria were seeded and to prevent 
evaporation, the sandwiched slides were placed in a humidified box 
during the stamping process. All experiments were conducted at 
37°C with a stamping time of 20 min.
Bacteria Staining: Using the I-Dot non-contact liquid dispenser, 
CTC solution (4  mm freshly prepared in medium) was printed onto a 
fluorinated glass slide (90 nL per spot). The CTC-stained slides were 
dried overnight and then exposed to bacteria using the same method 
used to transfer antibiotics; the stamping time was 10  min. After the 
addition of CTC, DMA slides loaded with bacteria-containing droplets 
were incubated for 3 h at 37°C.[21]
Imaging and Analyzing Growth of Bacteria: Before imaging, the DMA 
slide was dried for 10 min in the dark at room temperature to allow the 
bacteria to accumulate in a layer on the surface. Images of P. aeruginosa 
PAO1 GFP and CTC-stained P. aeruginosa PAO1 GFP were obtained 
manually with the Zeiss Axio Imager 2 microscope. To compare the 
fluorescence from bacteria in droplets on DMA slides and in 96-well 
plates, the bacteria suspension was transferred from the 96-well plate 
onto DMA slides to form droplets. After drying, squares on DMA slides 
were imaged.
ImageJ was used for image analysis. The mean fluorescent intensity 
of hydrophilic squares (the whole hydrophilic square) was measured. 
The mean intensity per pixel of the background was subtracted 
from this value to calculate the mean intensity produced by the GFP 
synthesized inside the bacteria. The background was detected on the 
superhydrophobic border within a square of 100 × 100 pixels.
Time-Kill Assay of Antibiotic on PAO1 on DMA Surface: To investigate 
the kinetics of antibiotic activity on DMA slides, suspensions of 
P. aeruginosa PAO1 (initial bacterial density OD600 = 1, 109 CFU mL−1, 
BM2 medium) with polymyxin B (40  µg mL−1) were incubated for a 
predetermined time (5, 10, 15, 30, 60, 120, 180, and 240  min) in a 
96-well plate (100  mL) and on a DMA slide (90 nL per droplet). To 
enumerate the bacteria on DMA slides, one of the three compartments 
in the DMA slide, which contained 196 bacterial droplets on its 
surface, was immersed into 20  mL BM2 medium and vortexed for 
60 s. The suspension was then serially diluted with cell wash buffer 
and 10  µL of the dilutions were seeded on Luria–Bertani broth (LB) 
agar plates. After incubation for 24 h at 37°C, the colony number on 
LB agar plates was recorded used to estimate the number of bacteria 
on the DMA slide. The number of bacteria per well in the 96-well plate 
was estimated in the same way following the culture of 17.6  µL of 
bacteria suspension.
Screening of Antibiotics on DMA Surfaces with Multi-Drug Resistant 
Strain P. aeruginosa PA49: Antibiotics (Table S3, Supporting 
Information) were printed onto fluorinated glass slides using the 
I-Dot. The amount printed was calculated according to the MIC and 
the droplet volume (90  nL for 1  mm squares). P. aeruginosa PA49 
suspension (106 CFU mL−1) was seeded onto DMA slides, which 
were then sandwiched with the antibiotic printed glass slides using 
the CSC instrument. The two surfaces were sandwiched at 37  °C for 
20  min before the antibiotic printed glass slide was removed and 
the DMA surface was incubated at 37  °C for 24 h. The same screen 
was performed in a 96-well plate, with antibiotics added directly into 
bacterial solution (100  µL) to obtain the same concentration as that 
of the bacterial droplets on the DMA surface. The solutions were then 
incubated at 37°C for 24 h. After incubation, the DMA surface was 
dried in air for 10 min.
Statistical Analysis: All data were represented as mean ± SD of n ≥ 
3 individual repetitions for each experiment. Experiments were at least 
repeated three times. The statistical significance of the experimental 
data was determined with a two-tailed Student t-test (p value <  0.05). 
The fitting curve of distribution of the volume of droplets in Figure  1d 
was plotted in OriginPro using “nonlinear curve fit” function: Gaussian 
model. Scan of fluorescence intensity in Figure  2d,f,h was measured 
with the “Plot Profile” function of ImageJ.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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